Gilead Sciences Share Price Today
(NASDAQ: GILD)

Name: Gilead Sciences Share Price Today (NASDAQ: GILD) - Gilead Sciences Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Gilead Sciences share price is $109.95 & ₹9,535.52 as on 22 Feb 2025, 2.30 'hrs' IST

$109.95

▲

-0.08

(-0.07%)

Market is closed - opens 8 PM, 24 Feb 2025

View live Gilead Sciences share price in Dollar and Rupees. Guide to invest in Gilead Sciences stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Gilead Sciences, along with analyst recommendations, forecasts, and comprehensive financials.

Gilead Sciences share price movements

Today's Low: $109.91
Today's High: $110.99
$109.95
0.04%
Downside
Day's Volatility :0.98%
Upside
0.94%
52 Weeks Low: $62.07
52 Weeks High: $111.03
$109.95
43.55%
Downside
52 Weeks Volatility :44.09%
Upside
0.97%

Gilead Sciences (GILD) Returns

Period	Gilead Sciences Inc.	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	21.51%	1.6%	2.7%
6 Months	42.87%	-5.8%	9.2%
1 Year	50.72%	-1.0%	22.0%
3 Years	79.89%	15.2%	44.9%

Gilead Sciences (GILD) Key Statistics

in dollars & INR

Previous Close	$110.03
Open	$110.73
Today's High	$110.99
Today's Low	$109.905
Market Capitalization	$137.1B
Today's Volume	$8.0M
52 Week High	$111.025
52 Week Low	$62.07
Revenue TTM	$28.8B
EBITDA	$13.6B
Earnings Per Share (EPS)	$0.38
PE Ratio	289.55
Dividend Yield	2.94%
Profit Margin	1.67%
Quarterly Earnings Growth YOY	0.26%
Return On Equity TTM	2.29%

How to invest in Gilead Sciences Stock (GILD) from India?

It is very easy for Indian residents to invest directly in Gilead Sciences from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Gilead Sciences stock in both Indian Rupees (INR) and US Dollars (USD). Search for Gilead Sciences or GILD on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Gilead Sciences or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Gilead Sciences shares which would translate to 0.008 fractional shares of Gilead Sciences as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Gilead Sciences, in just a few clicks!

Returns in Gilead Sciences (GILD) for Indian investors in Rupees

The Gilead Sciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Gilead Sciences investment value today

Current value as on today

₹1,55,369

Returns

₹55,369

(+55.37%)

Returns from Gilead Sciences Stock

₹50,720 (+50.72%)

Dollar Returns

₹4,649 (+4.65%)

Indian investors sentiment towards Gilead Sciences (GILD)

108.7%

Period: Jan 24, 2025 to Feb 23, 2025. Change in 30 Days versus previous period

Investment in Gilead Sciences Shares from India has grown by 108.7% over the past 30 days, indicating increased transactional activity.

108%

Period: Jan 24, 2025 to Feb 23, 2025. Change in 30 Days versus previous period

Search interest for Gilead Sciences Stock from India on INDmoney has increased by 108% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Gilead Sciences Stock (GILD Ticker)

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential US Bluechip Equity Fund Direct Plan Growth	113725	9939.56	2.87%
Motilal Oswal S&P 500 Index Fund Direct Growth	10751	67.62	0.23%
Aditya Birla Sun Life International Equity Fund Direct Plan Growth	2300	2.53	1.01%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	1879	181.14	1.04%
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	16176	0.00	0.75%

Global Institutional Holdings in Gilead Sciences

BlackRock Inc
9.78%
Vanguard Group Inc
9.27%
Capital World Investors
5.75%
State Street Corp
4.83%
Capital Research Global Investors
4.65%
Wellington Management Company LLP
2.86%

Analyst Recommendation on Gilead Sciences

Hold

47%Buy

52%Hold

0%Sell

Based on 38 Wall street analysts offering stock ratings for Gilead Sciences(by analysts ranked 0 to 5 stars)

Based on 38 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Gilead Sciences Stock (GILD)

What analysts predicted

Downside of 2.65%

Target:

$107.03

Current:

$109.95

Insights on Gilead Sciences Stock (Ticker Symbol: GILD)

Price Movement
In the last 7 days, GILD stock has moved up by 5.6%
Increasing Revenue
Gilead Sciences Inc. has shown positive revenue growth over the last four quarters. The company's revenue increased from $6.68 billion to $7.56 billion, averaging a 4.0% increase per quarter.
Increasing Net Profit
Gilead Sciences Inc. has shown positive profit trends over the last two quarters. The company's net profit increased from $1.25 billion to $1.78 billion, reflecting an average rise of 29.7% each quarter.
GILD vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 259.4% return, outperforming this stock by 178.0%

GILD Gilead Sciences Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$22.4B	↑ 1.46%
Net Income	$5.4B	↓ 1.26%
Net Profit Margin	23.99%	↓ 0.66%

	FY20	Y/Y Change
Revenue	$24.7B	↑ 9.98%
Net Income	$89.0M	↓ 98.35%
Net Profit Margin	0.36%	↓ 23.63%

	FY21	Y/Y Change
Revenue	$27.3B	↑ 10.6%
Net Income	$6.2B	↑ 6894.38%
Net Profit Margin	22.8%	↑ 22.44%

	FY22	Y/Y Change
Revenue	$27.3B	↓ 0.09%
Net Income	$4.6B	↓ 26.23%
Net Profit Margin	16.83%	↓ 5.97%

	FY23	Y/Y Change
Revenue	$27.1B	↓ 0.6%
Net Income	$5.7B	↑ 23.37%
Net Profit Margin	20.89%	↑ 4.06%

	FY24	Y/Y Change
Revenue	$28.8B	↑ 6.04%
Net Income	$480.0M	↓ 91.53%
Net Profit Margin	1.67%	↓ 19.22%

	Q3 FY23	Q/Q Change
Revenue	$7.1B	↑ 6.83%
Net Income	$2.2B	↑ 108.61%
Net Profit Margin	30.92%	↑ 15.08%

	Q4 FY23	Q/Q Change
Revenue	$7.1B	↑ 0.92%
Net Income	$1.4B	↓ 34.45%
Net Profit Margin	20.08%	↓ 10.84%

	Q1 FY24	Q/Q Change
Revenue	$6.7B	↓ 6.03%
Net Income	$-4.2B	↓ 391.81%
Net Profit Margin	-62.37%	↓ 82.45%

	Q2 FY24	Q/Q Change
Revenue	$6.9B	↑ 3.93%
Net Income	$1.6B	↓ 138.71%
Net Profit Margin	23.23%	↑ 85.6%

	Q3 FY24	Q/Q Change
Revenue	$7.5B	↑ 8.58%
Net Income	$1.3B	↓ 22.37%
Net Profit Margin	16.61%	↓ 6.62%

	Q4 FY24	Q/Q Change
Revenue	$7.6B	↑ 0.32%
Net Income	$1.8B	↑ 42.3%
Net Profit Margin	23.56%	↑ 6.95%

	FY19	Y/Y Change
Profit	$17.8B	↑ 2.89%

	FY20	Y/Y Change
Profit	$20.1B	↑ 13.18%

	FY21	Y/Y Change
Profit	$20.7B	↑ 2.92%

	FY22	Y/Y Change
Profit	$21.6B	↑ 4.44%

	FY23	Y/Y Change
Profit	$27.1B	↑ 25.4%

	FY24	Y/Y Change
Profit	$78.2M	↓ 99.71%

	Q3 FY23	Q/Q Change
Profit	$5.5B	↑ 6.36%

	Q4 FY23	Q/Q Change
Profit	$5.6B	↑ 1.28%

	Q1 FY24	Q/Q Change
Profit	$5.1B	↓ 7.58%

	Q2 FY24	Q/Q Change
Profit	$5.4B	↑ 5.28%

	Q3 FY24	Q/Q Change
Profit	$6.0B	↑ 10.47%

	Q4 FY24	Q/Q Change
Profit	$79.0M	↓ 98.68%

	FY19	Y/Y Change
Operating Cash Flow	$9.1B	↑ 8.86%
Investing Cash Flow	$-7.8B	↓ 154.45%
Financing Cash Flow	$-7.6B	↓ 38.03%

	FY20	Y/Y Change
Operating Cash Flow	$8.2B	↓ 10.67%
Investing Cash Flow	$-14.6B	↑ 86.96%
Financing Cash Flow	$770.0M	↓ 110.09%

	FY21	Y/Y Change
Operating Cash Flow	$11.4B	↑ 39.37%
Investing Cash Flow	$-3.1B	↓ 78.58%
Financing Cash Flow	$-8.9B	↓ 1252.86%

	FY22	Y/Y Change
Operating Cash Flow	$9.1B	↓ 20.31%
Investing Cash Flow	$-2.5B	↓ 21.24%
Financing Cash Flow	$-6.5B	↓ 27.13%

	FY23	Y/Y Change
Operating Cash Flow	$8.0B	↓ 11.75%
Investing Cash Flow	$-2.3B	↓ 8.15%
Financing Cash Flow	$-5.1B	↓ 20.78%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$1.8B	↓ 24.86%
Investing Cash Flow	$-229.0M	↓ 52.59%
Financing Cash Flow	$-1.5B	↑ 37.87%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$2.2B	↑ 23.52%
Investing Cash Flow	$-727.0M	↑ 217.47%
Financing Cash Flow	$-1.1B	↓ 27.6%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$2.2B	↑ 2.31%
Investing Cash Flow	$-2.2B	↑ 203.58%
Financing Cash Flow	$-1.4B	↑ 23.84%

Gilead Sciences Technicals Summary

Sell

Neutral

Buy

Gilead Sciences is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Gilead Sciences (GILD) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Gilead Sciences Inc.	15.31%	42.87%	50.72%	79.89%	47.19%
Eli Lilly And Company	8.11%	-8.08%	13.18%	248.29%	554.29%
Johnson & Johnson	6.15%	-1.4%	0.94%	-2.23%	12.96%
Merck & Co. Inc.	-8.62%	-23.02%	-30.53%	17.27%	11.96%
Novo Nordisk A/s	0.65%	-34.9%	-28.67%	71.45%	188.31%
Abbvie Inc	14.23%	2.35%	13.01%	35.13%	128.57%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Gilead Sciences Inc.	289.55	289.55	0.57	7.93	0.02	0.11	0.03	15.45
Eli Lilly And Company	74.67	74.67	0.88	23.1	0.84	0.15	0.01	15.81
Johnson & Johnson	27.58	27.58	1.0	10.57	0.2	0.08	0.03	29.7
Merck & Co. Inc.	13.01	13.01	0.07	8.99	0.42	0.11	0.04	17.58
Novo Nordisk A/s	26.33	26.33	1.2	0.0	0.81	0.22	0.02	32.31
Abbvie Inc	84.05	84.05	2.64	12.26	0.62	0.08	0.03	1.88

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Gilead Sciences Inc.	Hold	$137.1B	47.19%	289.55	1.67%
Eli Lilly And Company	Buy	$784.7B	554.29%	74.67	23.51%
Johnson & Johnson	Buy	$384.4B	12.96%	27.58	15.84%
Merck & Co. Inc.	Buy	$221.8B	11.96%	13.01	26.67%
Novo Nordisk A/s	Buy	$367.7B	188.31%	26.33	34.78%
Abbvie Inc	Buy	$354.6B	128.57%	84.05	7.59%

Gilead Sciences Dividend announcements

Gilead Sciences Dividends March, 2025
In the quarter ending March,2025. Gilead Sciences has declared dividend of $0.79
Read More

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Organization	Gilead Sciences
Employees	0
CEO	Mr. Daniel P. O'Day
Industry	Health Technology

Management People of Gilead Sciences

Name	Title
Mr. Daniel P. O'Day	Chairman & CEO
Mr. Andrew D. Dickinson	Chief Financial Officer
Ms. Deborah H. Telman J.D.	Executive VP of Corporate Affairs, General Counsel & Corporate Secretary
Ms. Johanna Mercier	Chief Commercial Officer
Ms. Sandra Patterson	Senior VP, Corporate Controller & Principal Accounting Officer
Ms. Jacquie Ross C.F.A.	Vice President of Investor Relations
Ms. Jyoti K. Mehra	Executive Vice President of Human Resources
Dr. Linda Slanec Higgins Ph.D.	Senior Vice President of Research, Innovation & Portfolio
Dr. Rudolf Ertl	Senior Vice President of Commercial Operations of Australia, Canada, Europe
Dr. Flavius Martin M.D.	Executive Vice President of Research

Important FAQs about investing in GILD Stock from India :

What is Gilead Sciences share price today?

Gilead Sciences share price today stands at $109.95, Open: $110.73 ; Previous Close: $110.03 ; High: $110.99 ; Low: $109.91 ; 52 Week High: $111.03 ; 52 Week Low: $62.07.

The stock opens at $110.73, after a previous close of $110.03. The stock reached a daily high of $110.99 and a low of $109.91, with a 52-week high of $111.03 and a 52-week low of $62.07.

Can Indians buy Gilead Sciences shares?

Yes, Indians can invest in the Gilead Sciences (GILD) from India.

With INDmoney, you can buy Gilead Sciences at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Gilead Sciences at zero transaction cost.

How can I buy Gilead Sciences shares from India?

It is very easy to buy Gilead Sciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Gilead Sciences (GILD) be purchased?

Yes, you can buy fractional shares of Gilead Sciences with INDmoney app.

What are the documents required to start investing in Gilead Sciences stocks?

To start investing in Gilead Sciences, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.